Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: Implications for immune-mediated cancer therapy

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Wilkinson Ryan, Ivy ^a   Kim, Julius ^b   Kim, Sojung ^a   Ak, Ferhat ^c   Dodson, Lindzy ^d   Colonna, Marco ^a   Powell, Matthew ^a   Mutch, David ^a   Spitzer, Dirk ^a   Hansen, Ted ^a   Goedegebuure, Simon P ^a   Curiel, David ^a   Hawkins, William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Saint Jans Gathuis Hospital Department of SJG Apotheek   (Netherlands)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; MESOTHELIN; PORCINE FIBER KNOB; UNCLASSIFIED DRUG; VIRUS FIBER PROTEIN; CAPSID PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HEXON CAPSID PROTEIN, ADENOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GENE TRANSFER; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PORCINE ADENOVIRUS; PROTEIN MODIFICATION; T LYMPHOCYTE; VIRUS INFECTIVITY; ANIMAL; BIOSYNTHESIS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PIG; PORCINE ADENOVIRUS A;

ADENOVIRIDAE; HUMAN ADENOVIRUS; MUS; PORCINE ADENOVIRUS 4; SUS;

ADENOVIRUSES, HUMAN; ADENOVIRUSES, PORCINE; ANIMALS; CAPSID PROTEINS; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; SWINE; TRANSDUCTION, GENETIC;

EID: 84928812108     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125851     Document Type: Article

References (50)

1. Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother. 2011; 60: 1097-1107. doi: 10.1007/s00262-011-1023-5 PMID: 21547597
2. Gregori S. Dendritic cells in networks of immunological tolerance. Tissue Antigens; 2011l; 77: 89-99. doi: 10.1111/j.1399-0039.2010.01615.x PMID: 21214520
3. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011; 269: 64-73. doi: 10.1111/j.1365-2796.2010.02317.x PMID: 21158979
4. Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011; 23: 21-27. doi: 10.1016/j.smim.2011.01.004 PMID: 21277223
5. Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother. 2012; 61: 223-230. doi: 10.1007/s00262-011-1138-8 PMID: 22065047
6. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18: 767-811. PMID: 10837075
7. Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013; 2: e22664. PMID: 23482679
8. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006; 100: 469-478. PMID: 16249018
9. Leao IC, Ganesan P, Armstrong TD, Jaffee EM. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci. 2008; 1: 228-239. doi: 10.1111/j.1752-8062.2008.00070.x PMID: 20357913
10. Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, et al. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One. 2012; 7: e46981. doi: 10.1371/journal.pone.0046981 PMID: 23056548
11. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol. 2009; 19: 165-178. doi: 10.1002/rmv.612 PMID: 19367611
12. Russell WC. Adenoviruses: update on structure and function. J Gen Virol. 2009; 90: 1-20. doi: 10.1099/vir.0.003087-0 PMID: 19088268
13. Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res. 2009; 143: 184-194. doi: 10.1016/j.virusres.2009.02.010 PMID: 19647886
14. Murakami M, Ugai H, Wang M, Belousova N, Dent P, et al. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations. Virology. 2010; 407: 196-205. doi: 10.1016/j.virol.2010.08.010 PMID: 20828776
15. McVey D, Zuber M, Ettyreddy D, Reiter CD, Brough DE, et al. Characterization of human adenovirus 35 and derivation of complex vectors. Virol J. 2010; 7: 276. doi: 10.1186/1743-422X-7-276 PMID: 20959004
16. Kim JW, Glasgow JN, Nakayama M, Ak F, Ugai H, et al. An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer. PLoS One. 2013; 8: e55533. doi: 10.1371/journal.pone.0055533 PMID: 23383334
17. Zajonc DM, Elsliger MA, Teyton L, Wilson IA (2003) Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol 4: 808-815. PMID: 12833155
18. van Kooten C, Banchereau J. CD40-CD40 ligand. Journal of Leukocyte Biology. 2000; 67: 2-17. PMID: 10647992
19. Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, et al. Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28. Journal of Biological Chemistry. 1995; 270: 21181-21187. PMID: 7545666
20. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992; 50: 373-381. PMID: 1735605
21. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. 2005; 13: 243-247. PMID: 16082249
22. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005; 124: 838-845. PMID: 16416732
23. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004; 279: 9190-9198. PMID: 14676194
24. Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 2012; 442: 293-302. doi: 10.1042/BJ20110282 PMID: 21999204
25. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One. 2012; 7: e33214. doi: 10.1371/journal.pone.0033214 PMID: 22485139
26. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012; 18: 858-868. doi: 10.1158/1078-0432.CCR-11-2121 PMID: 22147941
27. Hung CF, Calizo R, Tsai YC, He L, Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine. 2007; 25: 127-135. PMID: 16930783
28. Primeau T, Myers NB, Yu YY, Lybarger L, Wang X, et al. Applications of major histocompatibility complex class I molecules expressed as single chains. Immunol Res. 2005; 32: 109-121. PMID: 16106063
29. Lybarger L, Yu YY, Miley MJ, Fremont DH, Myers N, et al. Enhanced immune presentation of a singlechain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide. J Biol Chem. 2003; 278: 27105-27111. PMID: 12732632
30. Ho M, Hassan R, Zhang J, Wang QC, Onda M, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005; 11: 3814-3820. PMID: 15897581
31. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004; 200: 297-306. PMID: 15289501
32. BIMAS. National Institue of Health.
33. Li L, Herndon JM, Truscott SM, Hansen TH, Fleming TP, et al. Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine. 2010; 28: 1911-1918. doi: 10.1016/j.vaccine.2009.10.096 PMID: 20188246
34. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol. 2001; 75: 4176-4183. PMID: 11287567
35. Maizel JV Jr., White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968; 36: 115-125. PMID: 5669982
36. van de Ven R, Lindenberg JJ, Oosterhoff D, van den Tol MP, Rosalia RA, et al. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J Immunother. 2009; 32: 895-906. doi: 10.1097/CJI.0b013e3181b56deb PMID: 19816192
37. Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology. 2004; 322: 349-359. PMID: 15110532
38. Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine. 2009; 27: 7116-7124. doi: 10.1016/j.vaccine.2009.09.055 PMID: 19786146
39. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997; 185: 2043-2051. PMID: 9182675
40. Hohlfeld R, Engel AG (1994) The immunobiology of muscle. Immunol Today 15: 269-274. PMID: 8068173
41. Hemmi M, Tachibana M, Tsuzuki S, Shoji M, Sakurai F, et al. The early activation of CD8+ T cells is dependent on type I IFN signaling following intramuscular vaccination of adenovirus vector. Biomed Res Int. 2014; 2014: 158128. doi: 10.1155/2014/158128 PMID: 24971314
42. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010; 207: 1261-1271. doi: 10.1084/jem.20092618 PMID: 20479117
43. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med. 2010; 207: 1283-1292. doi: 10.1084/jem.20100223 PMID: 20479118
44. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther. 2004; 9: 712-720. PMID: 15120332
45. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 2000; 60: 5456-5463. PMID: 11034088
46. Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T, et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res. 2011; 71: 5827-5837. doi: 10.1158/0008-5472.CAN-11-0804 PMID: 21747119
47. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res. 2002; 8: 275-280. PMID: 11801569
48. Ulasov IV, Rivera AA, Han Y, Curiel DT, Zhu ZB, et al. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg. 2007; 107: 617-627. PMID: 17886563
49. Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, et al. A phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol. 2013; 130: 518-24. doi: 10.1016/j.ygyno.2013.06.003 PMID: 23756180
50. Stoff-Khalili MA, Rivera AA, Glasgow JN, Le LP, Stoff A, et al. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther. 2005; 12: 1696-1706. PMID: 16034451